Hepatitis C therapy before and after liver transplantation

Area of Science:

• Hepatology
• Transplantation Immunology
• Virology

Background:

• Recurrent hepatitis C virus (HCV) infection is a major cause of graft loss and patient mortality after liver transplantation.
• Current therapeutic options for managing recurrent HCV infection post-transplant are limited by tolerability and efficacy.
• HCV-infected liver transplant recipients require novel treatment strategies to improve outcomes.

Purpose of the Study:

• To review current therapeutic strategies for hepatitis C virus infection in liver transplant recipients.
• To evaluate the efficacy and limitations of pretransplant, preemptive, and posttransplant antiviral therapies.
• To highlight the unmet need for improved treatment options to prevent graft loss due to recurrent HCV.

Main Methods:

• Review of existing literature on antiviral therapies for hepatitis C virus in liver transplant settings.
• Analysis of data on pretransplant, preemptive, and posttransplant treatment regimens.
• Evaluation of treatment outcomes, including virologic response, sustained virologic response, and impact on survival.

Main Results:

• Pretransplant therapy shows promise for selected patients, with potential for pre-transplant viral clearance.
• Prophylactic therapies have proven ineffective; preemptive therapy is limited by tolerability.
• Posttransplant therapy with pegylated interferon and ribavirin achieves sustained virologic response in about 30% but is limited by tolerability and side effects.

Conclusions:

• Hepatitis C virus infection remains a significant challenge in liver transplant recipients.
• Current antiviral therapies have limitations in efficacy and tolerability, particularly post-transplant.
• Development of new, effective, and well-tolerated therapeutic options is crucial for improving long-term outcomes in HCV-infected liver transplant recipients.